Cargando…

Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study

OBJECTIVE: Plasma miRNAs represent potential minimally invasive biomarkers to monitor and predict outcomes from chemotherapy. The primary goal of the current study—consisting of patients with recurrent, platinum-resistant ovarian cancer—was to identify the changes in circulating miRNA concentrations...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benson, Eric A., Skaar, Todd C., Liu, Yunlong, Nephew, Kenneth P., Matei, Daniela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612782/ https://www.ncbi.nlm.nih.gov/pubmed/26485143 http://dx.doi.org/10.1371/journal.pone.0141279

Ejemplares similares

Decitabine reactivated pathways in platinum resistant ovarian cancer
por: Fang, Fang, et al.
Publicado: (2014)

The Ratio of Toxic-to-Nontoxic miRNAs Predicts Platinum Sensitivity in Ovarian Cancer
por: Patel, Monal, et al.
Publicado: (2021)

A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer
por: Glasspool, R M, et al.
Publicado: (2014)

Epigenetic synergy between decitabine and platinum derivatives
por: Qin, Taichun, et al.
Publicado: (2015)

Retrospective Analysis Of Comparative Outcomes In Recurrent Platinum-Sensitive Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (Lipo-Dox) And Carboplatin Versus Paclitaxel And Carboplatin
por: Weng, Chia-Sui, et al.
Publicado: (2019)

Pilot early phase II study of decitabine and carboplatin in patients with advanced melanoma
por: van der Westhuizen, Andre, et al.
Publicado: (2020)

Efficacy of birinapant in combination with carboplatin in targeting platinum-resistant epithelial ovarian cancers
por: Singh, Tanya, et al.
Publicado: (2022)

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer
por: McMeekin, S, et al.
Publicado: (2012)

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer
por: Sharma, R, et al.
Publicado: (2009)

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates
por: Liao, John B, et al.
Publicado: (2021)

Circulating Exosomal miRNAs as Biomarkers in Epithelial Ovarian Cancer
por: Shiao, Meng-Shin, et al.
Publicado: (2021)

A combination of circulating miRNAs for the early detection of ovarian cancer
por: Yokoi, Akira, et al.
Publicado: (2017)

Integrated bioinformatics analysis of validated and circulating miRNAs in ovarian cancer
por: Dogan, Berkcan, et al.
Publicado: (2022)

Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer(,,)
por: Kim, Kenneth H., et al.
Publicado: (2015)

Cost–utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing model
por: Lee, Hwa-Young, et al.
Publicado: (2013)

Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
por: Budden, Timothy, et al.
Publicado: (2018)

Recurrent Pseudomembranous Colitis in an Ovarian Cancer Patient Undergoing Carboplatin Chemotherapy
por: Allen, Valerie A., et al.
Publicado: (2016)

Comprehensive analysis on diagnostic value of circulating miRNAs for patients with ovarian cancer
por: Wang, Huiqing, et al.
Publicado: (2017)

Circulating miRNAs as Biomarkers for Endometriosis and Endometriosis-Related Ovarian Cancer—An Overview
por: Moga, Marius Alexandru, et al.
Publicado: (2019)

Circulating non-coding RNAs in recurrent and metastatic ovarian cancer
por: Schwarzenbach, Heidi, et al.
Publicado: (2019)

AKR1C1/2 inhibition by MPA sensitizes platinum resistant ovarian cancer towards carboplatin
por: Badmann, Susann, et al.
Publicado: (2022)

Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
por: Wagner, U, et al.
Publicado: (2012)

Weekly platinum chemotherapy for recurrent ovarian cancer
por: Clamp, A, et al.
Publicado: (2002)

Role of Circulating Biomarkers in Platinum-Resistant Ovarian Cancer
por: Sassu, Carolina Maria, et al.
Publicado: (2021)

Selinexor in Combination with Decitabine Attenuates Ovarian Cancer in Mice
por: Stiff, Patrick J., et al.
Publicado: (2023)

The expression of miRNAs is associated with tumour genome instability and predicts the outcome of ovarian cancer patients treated with platinum agents
por: Wang, Tianzhen, et al.
Publicado: (2017)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

An integrative analysis of cellular contexts, miRNAs and mRNAs reveals network clusters associated with antiestrogen-resistant breast cancer cells
por: Nam, Seungyoon, et al.
Publicado: (2012)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer
por: Sriramkumar, Shruthi, et al.
Publicado: (2022)

Circulating miRNAs as biomarkers for oral squamous cell carcinoma recurrence in operated patients
por: Yan, Yan, et al.
Publicado: (2016)

Surgery in platinum-resistant recurrent epithelial ovarian carcinoma
por: Zhao, Ling-Qin, et al.
Publicado: (2022)

NF-κB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer
por: Özeş, Ali R., et al.
Publicado: (2016)

EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells
por: Cardenas, Horacio, et al.
Publicado: (2016)

Role of Circulating miRNAs in Therapeutic Response in Epithelial Ovarian Cancer: A Systematic Revision
por: Ravegnini, Gloria, et al.
Publicado: (2021)

Recurrent transcriptional responses in AML and MDS patients treated with decitabine
por: Upadhyay, Pawan, et al.
Publicado: (2022)

Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
por: Colombo, Nicoletta, et al.
Publicado: (2019)

Circulating miRNAs as Biomarkers for Neurodegenerative Disorders
por: Grasso, Margherita, et al.
Publicado: (2014)

Circulating miRNAs as biomarkers of kidney disease
por: Hüttenhofer, Alexander, et al.
Publicado: (2017)

Platinum-Sensitive Recurrence in Ovarian Cancer: The Role of Tumor Microenvironment
por: Chien, Jeremy, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_d1sglqpdfae8stsavehs9d55kf